|Bid||9.11 x 800|
|Ask||9.21 x 800|
|Day's Range||8.60 - 9.17|
|52 Week Range||4.50 - 15.92|
|Beta (3Y Monthly)||2.13|
|PE Ratio (TTM)||N/A|
|Earnings Date||Mar 5, 2019 - Mar 11, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||17.33|
Want to participate in a research study? Help shape the future of investing tools and earn a $60 gift card! In December 2018, Xenon Pharmaceuticals Inc. (NASDAQ:XENE) released its most recent earnings announcement, which signall...
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today reported its financial results for the year ended December 31, 2018 and provided a corporate update. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “2018 was a pivotal year for Xenon as we built out our neurology pipeline and advanced multiple CNS product candidates using a variety of development strategies, including a ‘precision medicine’ approach to address rare pediatric disorders. Dr. Pimstone continued, “We have taken great care to create a diverse portfolio of therapeutic candidates, with a common focus on addressing neurological disorders.
NEW YORK, NY / ACCESSWIRE / March 6, 2019 / Xenon Pharmaceuticals Inc. (NASDAQ: XENE ) will be discussing their earnings results in their 2018 Fourth Quarter Earnings to be held on March 6, 2019 at 4:30 ...
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on March 5) AstraZeneca plc (NYSE: AZN ) Biohaven Pharmaceutical ...
Xenon Pharmaceuticals Inc. (XENE), a clinical-stage biopharmaceutical company, today announced that it will report its 2018 financial and operating results after the close of U.S. financial markets on Wednesday, March 6, 2019. Xenon management will host a conference call and live audio webcast at 4:30 pm Eastern Time (1:30 pm Pacific Time) to discuss the results and to provide a corporate update. To participate in the call, please dial (855) 779-9075, or (631) 485-4866 for international callers, and provide conference ID number 1545448.
SAN FRANCISCO, Feb. 26, 2019 /PRNewswire/ -- As Rare Disease Day focuses attention on the challenges of diagnosing rare, often genetic conditions, BioMarin Pharmaceutical Inc. (BMRN), Invitae Corporation (NVTA), Stoke Therapeutics and Xenon Pharmaceuticals (XENE) today announced the expansion of Behind the Seizure, an innovative, cross-company collaboration that aims to provide faster diagnosis for young children with epilepsy. Previously available to patients ages 2-4 years, the program will expand eligibility to make no-cost genetic testing available for healthcare providers to order for children who have had an unprovoked seizure from birth up to age five (0 to 60 months).
BURNABY, British Columbia, Jan. 28, 2019 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided regulatory updates on XEN007 and XEN1101, two therapeutic candidates from its CNS pipeline. The U.S. Food and Drug Administration (FDA) has granted rare pediatric disease (RPD) designation for the treatment of Alternating Hemiplegia of Childhood (AHC) with XEN007 (active ingredient flunarizine).
Every investor in Xenon Pharmaceuticals Inc. (NASDAQ:XENE) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it's not unusual to see Read More...
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided a corporate update and outlined its anticipated key milestone events in 2019. Dr. Simon Pimstone, Xenon’s Chief Executive Officer, said, “Xenon is entering 2019 in a strong position, poised to support multiple neurology programs that are expected to be in Phase 2 or later stage development this year. With four distinct therapeutic candidates – XEN496, XEN1101, XEN901 and XEN007 – that are aimed at treating neurological disorders, including epilepsy, we intend to pursue a variety of development strategies, such as those focused on using a ‘precision medicine’ approach to address rare pediatric disorders including KCNQ2 epilepsy as well as those targeting broader patient populations, including adult patients with focal epilepsy.
Eversept Partners is a New York-based hedge fund that focuses on investing in companies from the healthcare sector. It was founded by its current portfolio manager Mr. Kamran Moghtaderi, who previously worked as an Analyst and Portfolio Manager at Apis Capital Advisors, LLC. Mr. Moghtaderi’s investment experience is much more extensive than this, as prior […]
A whopping number of 13F filings filed with U.S. Securities and Exchange Commission has been processed by Insider Monkey so that individual investors can look at the overall hedge fund sentiment towards the stocks included in their watchlists. These freshly-submitted public filings disclose money managers’ equity positions as of the end of the three-month period […]
Xenon Pharmaceuticals Inc. (XENE), a clinical stage biopharmaceutical company, today provided clinical updates on XEN1101, a Kv7 potassium channel modulator being developed for the treatment of epilepsy and potentially other neurological disorders and XEN901, a potent, highly selective Nav1.6 sodium channel inhibitor being developed for the treatment of epilepsy. Xenon announced final results from its XEN1101 Phase 1 clinical trial and the related transcranial magnetic stimulation (TMS) studies, along with interim results from its XEN901 Phase 1 clinical trial, in posters at the American Epilepsy Society (AES) Annual Meeting held in New Orleans, LA.
BURNABY, British Columbia, Nov. 30, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will host a conference.
Warren Lammert founded Granite Point Capital, a long/short hedge fund with a focus on small-cap companies, in January 2004. The fund is headquartered in Boston, Massachusetts, and Mr. Lammert is its portfolio manager. Prior to launching his own fund, Warren Lammert honed his investment acumen for 14 years at Janus Capital Management LLC as a […]
Simon Pimstone has been the CEO of Xenon Pharmaceuticals Inc (NASDAQ:XENE) since 2003. First, this article will compare CEO compensation with compensation at similar sized companies. Next, we’ll consider growth Read More...
NEW YORK, Nov. 15, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
BURNABY, British Columbia, Nov. 07, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that Dr. Simon Pimstone,.
The Burnaby, British Columbia-based company said it had a loss of 63 cents per share. Losses, adjusted for non-recurring costs, were 33 cents per share. Xenon Pharmaceuticals shares have more than tripled ...
Robust, Novel Pipeline of Neurology Candidates Advancing in Clinical Development Conference Call at 4:30 pm ET Today BURNABY, British Columbia, Nov. 06, 2018 -- Xenon.
BURNABY, British Columbia, Oct. 30, 2018 -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a clinical-stage biopharmaceutical company, today announced that it will report its third.
A steady influx of foreign as well as domestic investments in U.S. healthcare has gone a long way in boosting gains for the space.